KELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company’s collaborators from the University of Michigan will present two scientific posters in the upcoming Society for Neuroscience (SfN) Conference, to be held from November 12-16, 2022 in San Diego.

Details of the poster presentations are as follows:

Title: Psilocybin Attenuates Mechanical Allodynia and Thermal Hyperalgesia in a Rodent Model of Formalin-Induced Chronic Pain
Presenting Author: Dr Nick Kolbman, University of Michigan
Co-authors: B. H. Silverstein,^1, T. Liu,¹ P. Guzzo,² J. P. Gilligan,² G. A. Mashour,^1, G. Vanini,¹ D. Pal¹
(¹ University of Michigan, ² Tryp Therapeutics)

The study results demonstrated that a single intravenous dose of psilocybin can attenuate mechanical allodynia and thermal hyperalgesia for up to 4 weeks post dose.

Title: Intravenous Psilocybin Alters Brain Network Dynamics in Rats
Presenting Authors: B.H. Silverman, University of Michigan
Co-authors: N. Koblman1,2,3, T. Liu1, P. Guzzo6, J. Gilligan6, G. A. Mashour1,2,3,4, G. Vanini 1,2,4, D. Pal1,2,4,5;
(1Dept. of Anesthesiol., 2Ctr. for Consciousness Sci., 3Dept. of Pharmacol., 4Neurosci. Grad. Program, 5Dept. of Mol. & Integrative Physiol., Univ. of Michigan, Ann Arbor, MI; 6Tryp Therapeut.)

This study demonstrated a change in EEG recordings in rats receiving an IV infusion of psilocybin coincident with achieving the psychedelic state.

Jim Gilligan, Chief Executive Officer, stated, “We are excited our collaborators at the University of Michigan are presenting the results of our two recent studies. The first study explored intravenous psilocybin and its effect in a recognized rat model of fibromyalgia. This model exhibits increased sensitivity to touch and hypersensitivity to elevated temperatures. Administration of a single intravenous infusion of psilocybin resulted in a decrease in both pain and heat sensitivity persisting until the end of the study (28 days). Tryp is the first company to pursue the use of psychedelics in nociplastic pain indications including fibromyalgia. These results support the potential clinical utility of psilocybin assisted therapy in the treatment of patients with fibromyalgia.

“The second study demonstrated a change in EEG recordings coincident with achieving the psychedelic state. Rats received a continuous intravenous infusion of psilocybin over a period of 60 minutes while EEG data were simultaneously monitored. The results demonstrate the ability to detect changes in EEG patterns coincident with attaining the psychedelic state. In addition, upon cessation of the infusion a return to baseline EEG patterns correlated with decreasing blood levels of psilocin. This study will help facilitate Tryp’s program to utilize EEG recordings to optimize dose and infusion rates of TRP-8803 (IV psilocin) in planned upcoming clinical trials.”

About Tryp Therapeutics

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN) program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The Company has begun enrolling patients in its Phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information, please visit www.tryptherapeutics.com.

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans,” “targets,” “expects” or “does not expect,” “is expected,” “an opportunity exists,” “is positioned,” “estimates,” “intends,” “assumes,” “anticipates” or “does not anticipate” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might,” “will” or “will be taken,” “occur” or “be achieved.” In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information
John Nesbett/Jennifer Belodeau
IMS Investor Relations
51 Locust Avenue, New Canaan, CT
[email protected]
203.972.9200

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) set out to build a nationwide network of psychedelic-assisted psychotherapy clinics in 2018. Since then, the company has grown its footprint to ten clinics across six states exceeding 60,650 sq. ft. of space and clinical capacity for more than 120 treatment rooms, with more to come.

The company believes that each treatment room could accommodate up to four visits per day at $490 per visit. Using these assumptions, the company’s 120+ treatment rooms could generate upwards of $60 million in annual revenue. 

These estimates aren’t merely guesses, either. The company recently reported $1.55 million in revenue and an estimated $1.17 million in gross income for the ten months leading up to October 31, 2021. These figures were double those from one year ago and come mainly from organic growth at its flagship clinic in Knoxville, TN.

Beyond Physical Clinics

Revitalist hasn’t limited its focus to physical clinics. Next year, the company plans to launch its telemedicine platform targeting psychedelic therapies. As a result, the company could reach millions more people around the country beyond the reach of its network of clinics and provide better support to those who go into its clinics.

In November, the company also announced the acquisition of a 60% interest in Revitaland Meta Tech Inc. to create virtual clinics in the metaverse. The virtual world will enable patients and medical professionals to interact without being in the same physical space, improving accessibility without compromising the experience.

While the metaverse may seem far-fetched to many, Facebook’s move to rename its business “Meta” underscores just how central the concept is to tech giants. In addition, the COVID-19 pandemic and the rise of remote working are also pushing many consumers toward virtual meetings in the metaverse that could quickly become a ubiquitous environment.

Significant Potential

Revitalist’s significant progress in building out its physical and virtual clinic network and presence reflects the strength of its leadership team. In addition to its unparalleled medical expertise, the team includes veteran financiers and project managers that have a track record of growing $100+ million businesses.

CEO Katie Walker discusses the company’s growth strategy

Management hopes to build a network of nearly 50 clinics in 2022 before reaching more than 150 clinics by 2025. After establishing a footprint in the U.S., the company aims to expand to international locations in jurisdictions. These ambitions could yield a company generating upwards of $100 million in annual revenue at attractive gross margins.

And, while these plans may seem ambitious on the surface, Stifel GMP research suggests that psychedelic-assisted psychotherapy (PAP) clinics have a total addressable market of over $10 billion in the U.S. alone. As a result, the company has significantly greater potential than its immediate plans over the long term to capitalize on the massive market.

Looking Ahead

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) represents a compelling opportunity to invest in the growth of psychedelic-assisted therapies—a field that many experts believe could revolutionize mental health treatments worldwide. As the company continues to expand, investors may want to take a closer look at the stock.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

By LARRY LAGE AP Sports Writer

Calvin Johnson is simply in awe that he has joined Jim Brown and Gale Sayers as Pro Football Hall of Famers inducted at 35 years old or younger.

“That’s football royalty, man,” Johnson said in an interview with The Associated Press. “When you hear those guys’ names, you’re just like, ‘Wow.’”

The relatively young man, known as Megatron when he was a Detroit Lions receiver, plans to make the most of a post-playing career. He aims to change the conversation about cannabis and help improve the lives of people whether or not they want to partake.

Johnson and former Lions teammate Rob Sims founded Michigan-based Primitiv, a cannabis research company, and created a collaboration with Harvard University to research how marijuana can help people with CTE and chronic pain.

“What he’s trying to do here is really, really powerful – in being able to create collaborations that can help find a solution to players who are transitioning out of the NFL,” Harvard Medical School professor Wilfred Ngwa said.

Johnson will also be the face and voice of a new app created by NESTRE, a Florida-based company focused on increasing brain health and mental wellness.

“It’s not often that you spend time with a Hall of Famer, but at the same time somebody that is just a genuinely good person, no ego,” Tommy Shavers, founder and CEO of NESTRE.

Johnson was unassuming around reporters throughout his nine-season career with the Lions, usually shrugging his shoulders and coming up with an aw-shucks answer to questions about his play.

Teammates raved about how he worked out as if he was competing for the final spot on the roster.

“He’s not a diva, as they say, as some receivers tend to be,” said Derrick Moore, who introduced Johnson during his Pro Football Hall of Fame induction.

His humility is still on display for all those who cross his path, but he is much more passionate when he talks about his post-playing career than he was about anything related to football.

Johnson warmly welcomed visitors at Primitiv’s 12,000-suare foot cultivation facility, holding doors open, handing out scrubs and collected laundry.

And, he didn’t just do that for the cameras.

“Arguably the greatest receiver in the history of the game is in here mopping floors,” Sims said.

Johnson, though, has a side of him that is not so pleasant and it can been seen and heard when discussing his feelings about the Lions.

When Johnson retired in March, 2016, the team compelled him to pay back more than $1 million of the signing bonus from his eight-year deal that was could’ve potentially paid him $132 million and kept him under contract through the 2019 season.

Hard feelings? Yep.

“Of course,” he acknowledged. “That’s the reason I am not going back over there.”

Lions president Rod Wood has said the team is continuing to communicate with Johnson. The team would love to have Johnson come a game this season to celebrate his Hall of Fame induction, but he’s not interested.

“If someone comes in your pocket and says, `Hey I’m gonna take this $200 from you and I still want you to be my friend and come over to my house tomorrow,’” Johnson said. “What are you gonna do? Hell, no.”

Johnson’s retirement rekindled memories of how Hall of Fame running back Barry Sanders left Detroit shortly before the 1999 season. Sanders, too, had a rift with the Lions perhaps in part because he had to return $1.8 million of his signing bonus to them. Three years ago, the team paid him to be an ambassador and he attends functions for the franchise.

If the Lions return the money Johnson had to pay back, he said everyone will know.

“You’ll see me around the team,” he said.

Detroit drafted Johnson out of Georgia Tech with the No. 2 pick in 2007 and had a winning record in just two of his nine seasons.

Despite sometimes drawing two defensive backs as if he was lined up wide for a punt team, he was tough to stop because of his size, speed and strength.

The 6-foot-5, 237-pound receiver could run the 40-yard dash in 4.4 seconds, and clear 45 inches with his vertical jump.

Johnson’s skill set helped him break one of Hall of Famer Jerry Rice’s records with 1,964 yards receiving in 2012. The three-time All-Pro and six-time Pro Bowl player reached 10,000 yards receiving (115 games) and 11,000 yards (127 games) yards quicker than anyone in NFL history. He also set a league record with 86.1 yards receiving per game, a mark that Julio Jones has surpassed.

Even though his career was relatively short, he made enough of an impact to be enshrined with greats of the game.

In the end, though, he wants to be known for much more than what he did on the football field.

“Yeah, football, Hall of Fame, that’s a great legacy,” Johnson said. “But I would love for my legacy to be able to create something here that goes beyond, creating that quality of life for people and so many different applications. That’s what I’m all about.”

The idea of your dog taking marijuana products can be scary. You don’t know how they might react to the effects. Don’t worry, though, CBD won’t make your dog high because it is not psychoactive.

CBD is one of the cannabinoids found in marijuana. Unlike THC (Tetrahydrocannabinol), which is psychoactive, CBD is known more for its anti-inflammatory and antioxidant properties.

Humans have used cannabis for over a thousand years to treat various illnesses. Now, many pet owners are turning to cannabis products to treat their sick pets as well and finding it very beneficial.

Cannabinoids like CBD are potential treatments for various diseases, including inflammatory bowel disease, chronic pain, lack of appetite, and epilepsy. CBD is also used in the management of cancer, nausea, and vomiting.

Dogs have an endocannabinoid system similar to that of humans. It means that a substance that affects the human endocannabinoid system will affect dogs in the same way.

Many pet owners are turning to CBD oil for dogs. Here is why:

1. It Relieves Stress and Anxiety

Does your dog have separation or noise anxiety? Does it bark a lot and get jittery when you leave? CBD may help.

CBD binds to dogs’ endocannabinoid system and helps in balancing emotions. When you give a dog CBD, the drug is known to intiate neurotransmitters that convey hormones that calm the dog when stressed.

CBD is not only useful for dogs with separation anxiety but also phobia. If your dog can’t be around people, you can try giving it some CBD.

2. Improves Brain Function

When you bond with your dog, you become lifetime friends. Sadly, dogs do not live as long as humans. They have a lifespan of about 13 years. Your dog will start aging rapidly after about eight years. This can be a sad process as its brain starts to waste.

Inflammatory Central Nervous System (CNS) Disease is common in older dogs. When a dog has CNS, it may lose the sense of its environment. Communicating with it will become difficult, and it may lose its way around frequently.

Endocannabinoids play a key role in modulating neurotransmitter activity in the CNS system. This provides evidence that the dysfunction of the cannabinoid system contributes to canine inflammatory CNS diseases.

Placing your aging dog on CBD therapy can help boost its endocannabinoid system. CBD supports mitochondria development and cellular function. CBD is also known to have anti-inflammatory benefits, which improve brain health.

3. CBD Treats Itchiness

You probably have a dog that itches a lot, and no medication seems to work. The cause may be food, fleas, or lice. Some dogs seem to respond better to these allergies than others. The secret is that they have a strong immune system.

CBD offers relief for many allergic reactions in dogs such as dermatitis. The anti-inflammatory properties in CBD can be useful for itchy dogs. CBD can also boosts the dog’s immunity, giving it a better chance to manage allergies.

4. CBD Increases Appetite

Is your dog giving you trouble eating and you can’t find a solution? Dogs need to have a good appetite because that is what makes them healthy.

If the dog is unwell it may have nausea, which may cause a lack of appetite. Without eating, your dog may not have a good chance of fighting off diseases.

CBD can stimulate appetite and help dogs that are struggling to eat. CBD can also help sick dogs relax and get quality sleep, which is helpful for healing.

5. CBD Relieves Pain

Chronic pain is a prevalent condition in dogs. This type of pain is maladaptive as it does not offer any protective function. Pain causes stress in dogs and takes out their joy. If your pet seems dull, it could possibly be suffering from chronic pain.

CBD can be efficient in treating hard to treat pain. It also is known to have anti-inflammatory properties that help reduce inflammation that causes pain. The endocannabinoid receptors that CBD binds to also help modulate pain transmission.

While CBD is not a conventional treatment for dogs, many holistic veterinary practitioners recommend CBD for dogs suffering from joint pain. Joint pain caused by arthritis is common in aging dogs.

CBD can relax the nerves and help soothe the pain resulting from damaged nerves or cartilage. CBD can also be beneficial in alleviating intestinal inflammation.

6. CBD is natural and Non-toxic

If you are worried about CBD toxicity, worry not. Many studies that focus on the toxicity of marijuana look at the psychoactive element THC and not CBD in isolation.

CBD is not psychoactive, and it will not give the euphoric high associated with marijuana. CBD contains therapeutic properties without the psychoactive element.

There is no toxicity associated with CBD. You don’t have to worry about your dog overdosing and getting sick from CBD.

What this all Means

CBD is seen as a revolutionary treatment for many diseases in humans and now the benefits are being extended to dogs. CBD is not only known to offer relief from ailments, but it also can improve the overall health of the dog.

There is limited research on the benefits of CBD to dogs. However, initial studies show promising outcomes with fears of toxicity having been ruled out. Some dog owners and vets are already experimenting with CBD on their sick dogs. While there is still a long way to go, the results show great potential.

Dogs tend to become a part of the family quickly. We are very connected to our furry friends, and we tend to notice everything that happens to them.

Most dog owners are always on the lookout for tips to keep their pets healthy and in a good mood. CBD is the latest thing in dog food supplementation and many are still unsure when and why to add this to their dog’s diet.

We’re going to discuss the benefits, potential side effects, and right dosage of CBD for your dog so you can use it safely and without worry. To see an example of a specialized dog CBD product, click here.

For another interesting article on this topic Click Here

Since dogs have, more or less, the same endocannabinoid system as humans, they can reap the same benefits as us. Here are the conditions that CBD may help dogs overcome or at least keep under control.

1. Pain relief – One of the primary uses of CBD in humans and dogs is to assist with managing chronic pain. This is especially true when talking about neuropathic pain. If your dog has a condition he/she deals with daily, CBD use should be a serious consideration.
2. Anti-Anxiety – Dogs can develop anxiety due to multiple reasons. For example, they may have survived abuse or were abandoned, so they develop separation anxiety. If you notice your dog experiencing excessive fear and anxiety CBD can help manage that.
3. Seizures and spasms – CBD is a natural anticonvulsant, and as such, it can be suitable for treatment and prevention of spasms, tics, seizures, and tremors of various sorts.
4. Improved appetite – This is a commonly discussed benefit of CBD use. Keep in mind, if your dog gets its appetite back and starts getting overweight, you should stop using CBD as they no longer need it.
5. Insomnia – Sleeplessness is a dreadful condition making dogs lose focus, unable to hold their temper, making them irritable, etc. CBD is often used to improve sleep and can help with long-term sleep regulation.
6. Skin conditions – Due to the connection between the endocannabinoid system and skin regulation, CBD can help with rashes, scar healing, etc.

There are numerous other possible benefits, but we wanted to show you the most widespread reasons animal lovers consider using CBD with their dogs. Let’s see what some of the potential downsides of CBD use are.

The most well known side-effect of using CBD to treat dogs is possible sleepiness (which is the desired effect in some cases).

Keep in mind that cannabis is not typically considered safe for your dog, and the reason is that it contains THC. However, a dog targeted CBD hemp oil does not have dangerous THC levels, even though some human variants might. In a lot of cases, people give their dogs CBD oil intended for human use, and the THC levels are not always appropriate for animal use, so keep in mind that they can’t always be used interchangeably.

The reason why people tend to do this is that dog CBD products tend to be more expensive, but in most cases, the money isn’t worth the hustle of worrying if you did everything right.

This is where it gets a bit tricky.

The right dosage for your dog will depend on two things:

1. Your dog’s weight;
2. The strength of the formula you are giving them;

The math you should be doing when calculating for your dog’s weight is this: 0.2mg of CBD per pound.

Most CBD products have a specific formula strength, and it is usually displayed on the label. This shows how many mg of CBD the liquid contains per ml. For example, a 75 mg formula usually contains 2.5 mg of CBD per ml. However, there can be other variations of formula strength and these should be considered before actually giving any CBD product to your dog.

This means that a dog that weighing 25 pounds, using a 75 mg formula should get 2 ml of CBD to hit that 5 mg sweet spot intended for its weight.

The general advice is to start with a dosage smaller than the proposed dosage and take it from there. Sometimes you won’t even need to max out the suggested dosage to get the benefits you are after. This is especially true if you are giving your dog CBD just for the general benefits.

For more information on how to better understand dosage Click Here

We hope we managed to make the use of CBD for dogs a bit less of a mystery. Of course, before you give your dog CBD, you should consult a vet and see if your dog can manage the therapy.

The CBD products intended for dogs make things quite a bit easier as the treats and oils come with dosage instructions and don’t contain anything that may harm your dog. Good luck!